HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Long-term remission of ocular and extraocular manifestations in Behçet's disease using infliximab.

AbstractOBJECTIVES:
To investigate the long-term effect of infliximab on ocular and extraocular manifestations in patients with Behçet's disease.
METHODS:
Seven patients with active Behçet's disease and treated with infliximab at Aichi Medical University Hospital for more than 18 months were included in the study. We evaluated visual acuity, the average number of uveitis attacks involving the posterior segment, and general disease activity every 2 months. The Behçet's Disease Current Activity Form (BDCAF) was used for an overall index of disease activity. Anti-infliximab antibody levels were examined in the patients' sera.
RESULTS:
The follow-up period after initial introduction of infliximab ranged from 19 to 40 months (mean ± SD, 32 ± 8.7 months). The number of infliximab infusions ranged from 12 to 24 (19 ± 4.4). By the 2-month follow-up, the frequency of uveitis attacks involving the posterior segment and the BDCAF scores were significantly improved compared to the 2 months before introducing infliximab. Anti-infliximab antibodies were detected in the sera of all examined patients.
CONCLUSIONS:
Significant long-term improvement in both the frequency of uveitis attacks involving the posterior segment and overall disease activity was provided by the administration of infliximab to patients suffering from Behçet's disease, despite the presence of anti-infliximab antibodies.
AuthorsTsuneaki Handa, Hinako Tsunekawa, Masahiko Yoneda, Daisuke Watanabe, Tomoyuki Mukai, Masahiro Yamamura, Masayoshi Iwaki, Masahiro Zako
JournalClinical and experimental rheumatology (Clin Exp Rheumatol) 2011 Jul-Aug Vol. 29 Issue 4 Suppl 67 Pg. S58-63 ISSN: 0392-856X [Print] Italy
PMID21968238 (Publication Type: Journal Article)
Chemical References
  • Anti-Inflammatory Agents
  • Antibodies
  • Antibodies, Monoclonal
  • Infliximab
Topics
  • Adult
  • Anti-Inflammatory Agents (therapeutic use)
  • Antibodies (blood)
  • Antibodies, Monoclonal (immunology, therapeutic use)
  • Behcet Syndrome (complications, drug therapy, immunology)
  • Female
  • Follow-Up Studies
  • Gastrointestinal Diseases (drug therapy, etiology, immunology)
  • Humans
  • Infliximab
  • Joint Diseases (drug therapy, etiology, immunology)
  • Male
  • Oral Ulcer (drug therapy, etiology, immunology)
  • Remission Induction
  • Retrospective Studies
  • Severity of Illness Index
  • Uveitis, Posterior (drug therapy, etiology, immunology)
  • Young Adult

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: